GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Karo Pharma AB (Karo Pharma AB) Cash, Cash Equivalents, Marketable Securities : $35.2 Mil (As of Jun. 2022)


View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Cash, Cash Equivalents, Marketable Securities?

Karo Pharma AB's quarterly cash, cash equivalents, marketable securities declined from Sep. 2021 ($43.81 Mil) to Dec. 2021 ($28.68 Mil) but then increased from Dec. 2021 ($28.68 Mil) to Jun. 2022 ($35.19 Mil).

Karo Pharma AB's annual cash, cash equivalents, marketable securities increased from Dec. 2019 ($26.38 Mil) to Dec. 2020 ($68.20 Mil) but then declined from Dec. 2020 ($68.20 Mil) to Dec. 2021 ($28.68 Mil).


Karo Pharma AB Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Karo Pharma AB's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Cash, Cash Equivalents, Marketable Securities Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.92 44.14 26.38 68.20 28.68

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.59 62.29 43.81 28.68 35.19

Karo Pharma AB Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Karo Pharma AB  (OTCPK:KARBF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Karo Pharma AB Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Karo Pharma AB (Karo Pharma AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire 06-25-2019